Menu
GeneBe

LITAF

lipopolysaccharide induced TNF factor

Basic information

Region (hg38): 16:11547721-11636381

Links

ENSG00000189067NCBI:9516OMIM:603795HGNC:16841Uniprot:Q99732AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Charcot-Marie-Tooth disease type 1C (Strong), mode of inheritance: AD
  • Charcot-Marie-Tooth disease type 1C (Supportive), mode of inheritance: AD
  • Charcot-Marie-Tooth disease (Moderate), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Charcot-Marie-Tooth disease, type 1CADGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingNeurologic11713717; 12525712; 19541485; 20301384; 23319192

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the LITAF gene.

  • Charcot-Marie-Tooth disease type 1C (181 variants)
  • not provided (87 variants)
  • Inborn genetic diseases (34 variants)
  • Charcot-Marie-Tooth disease (24 variants)
  • not specified (10 variants)
  • Charcot-Marie-Tooth disease, type I (8 variants)
  • Tip-toe gait (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the LITAF gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
32
clinvar
1
clinvar
35
missense
4
clinvar
3
clinvar
75
clinvar
4
clinvar
1
clinvar
87
nonsense
1
clinvar
1
start loss
2
clinvar
2
frameshift
1
clinvar
1
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
2
1
3
non coding
31
clinvar
22
clinvar
51
clinvar
104
Total 4 3 112 58 53

Variants in LITAF

This is a list of pathogenic ClinVar variants found in the LITAF region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-11547758-T-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)884699
16-11547767-G-A Charcot-Marie-Tooth disease, type I Uncertain significance (Jun 14, 2016)317751
16-11547784-T-C Charcot-Marie-Tooth disease type 1C Likely benign (Jan 12, 2018)317752
16-11548005-G-C Charcot-Marie-Tooth disease type 1C Benign (Jan 13, 2018)884700
16-11548010-C-T Charcot-Marie-Tooth disease type 1C Benign (Jan 13, 2018)317753
16-11548080-G-T Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 12, 2018)317754
16-11548144-A-C Charcot-Marie-Tooth disease type 1C Benign (Jan 12, 2018)317755
16-11548201-A-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)884701
16-11548215-T-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)884702
16-11548222-G-T Charcot-Marie-Tooth disease type 1C Benign (Jan 12, 2018)317756
16-11548238-G-T Charcot-Marie-Tooth disease type 1C Uncertain significance (Mar 30, 2018)885639
16-11548251-C-T Charcot-Marie-Tooth disease type 1C Uncertain significance (Apr 27, 2017)885640
16-11548273-T-G Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 12, 2018)885641
16-11548386-T-C Charcot-Marie-Tooth disease type 1C Benign (Jan 12, 2018)317757
16-11548420-T-G Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)885642
16-11548467-T-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)317758
16-11548583-T-G Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)885643
16-11548688-T-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)317759
16-11548704-G-A Charcot-Marie-Tooth disease type 1C Benign (Jan 13, 2018)317760
16-11548733-C-T Charcot-Marie-Tooth disease type 1C Benign (Jan 13, 2018)317761
16-11548755-C-T Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)317762
16-11548820-T-TA Charcot-Marie-Tooth disease, type I Uncertain significance (Jun 14, 2016)317763
16-11548821-A-T Charcot-Marie-Tooth disease type 1C Benign (Jan 12, 2018)317764
16-11548841-A-G Charcot-Marie-Tooth disease type 1C Benign (Jan 13, 2018)317765
16-11548914-T-C Charcot-Marie-Tooth disease type 1C Uncertain significance (Jan 13, 2018)317766

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
LITAFprotein_codingprotein_codingENST00000571688 388385
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.03080.823125734041257380.0000159
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.224971030.9380.000006351029
Missense in Polyphen2131.1160.67489342
Synonymous-0.1754846.51.030.00000333342
Loss of Function1.1335.990.5012.54e-768

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.00005450.0000544
Finnish0.000.00
European (Non-Finnish)0.000008830.00000879
Middle Eastern0.00005450.0000544
South Asian0.00006530.0000653
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Plays a role in endosomal protein trafficking and in targeting proteins for lysosomal degradation (PubMed:23166352). Plays a role in targeting endocytosed EGFR and ERGG3 for lysosomal degradation, and thereby helps downregulate downstream signaling cascades (PubMed:23166352). Helps recruit the ESCRT complex components TSG101, HGS and STAM to cytoplasmic membranes (PubMed:23166352). Probably plays a role in regulating protein degradation via its interaction with NEDD4 (PubMed:15776429). May also contribute to the regulation of gene expression in the nucleus (PubMed:10200294, PubMed:15793005). Binds DNA (in vitro) and may play a synergistic role with STAT6 in the nucleus in regulating the expression of various cytokines (PubMed:15793005). May regulate the expression of numerous cytokines, such as TNF, CCL2, CCL5, CXCL1, IL1A and IL10 (PubMed:10200294, PubMed:15793005). {ECO:0000269|PubMed:15793005, ECO:0000269|PubMed:23166352, ECO:0000303|PubMed:15776429, ECO:0000305|PubMed:10200294}.;
Disease
DISEASE: Charcot-Marie-Tooth disease 1C (CMT1C) [MIM:601098]: A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot- Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. {ECO:0000269|PubMed:12525712, ECO:0000269|PubMed:15776429, ECO:0000269|PubMed:15786462, ECO:0000269|PubMed:16118794, ECO:0000269|PubMed:21896645, ECO:0000269|PubMed:23166352, ECO:0000269|PubMed:24604904}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in LITAF may be involved in extramammary Paget disease (EMPD) carcinogenesis. EMPD is a cancerous disease representing about 8% of all malignant skin cancers; it usually appears in the anogenital area and can be fatal by metastasizing to internal organs when left untreated for a long time. The clinical features are usually those of eczematous eruptions with weeping and crust formation. {ECO:0000269|PubMed:15197774}.;
Pathway
Lysosome - Homo sapiens (human) (Consensus)

Recessive Scores

pRec
0.207

Intolerance Scores

loftool
0.0585
rvis_EVS
-0.05
rvis_percentile_EVS
50.01

Haploinsufficiency Scores

pHI
0.253
hipred
Y
hipred_score
0.583
ghis
0.508

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.212

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Litaf
Phenotype
cellular phenotype; homeostasis/metabolism phenotype; immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hematopoietic system phenotype;

Gene ontology

Biological process
regulation of cytokine production;regulation of transcription by RNA polymerase II;aging;positive regulation of I-kappaB kinase/NF-kappaB signaling;positive regulation of transcription by RNA polymerase II;cellular response to lipopolysaccharide;negative regulation of NIK/NF-kappaB signaling
Cellular component
Golgi membrane;nucleoplasm;lysosomal membrane;Golgi apparatus;cytosol;plasma membrane;cytoplasmic side of plasma membrane;intracellular membrane-bounded organelle;cytoplasmic side of early endosome membrane;cytoplasmic side of late endosome membrane;cytoplasmic side of lysosomal membrane
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription activator activity, RNA polymerase II-specific;protein binding;zinc ion binding;WW domain binding